Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) is an inhibitory protein that competitively binds to B7 molecules (CD80 and CD86) in competition with CD28 (63), exerting immune co-suppressive responses (64), making it a highly regarded therapeutic target in the treatment of autoimmune diseases. Here, CD86 is linked to autoimmune disease.